Get the Daily Brief
Latest Biotech News
PacBio Lowers Genome Cost: Reusable consumables cut prices to <$300
Pacific Biosciences announced a program to allow select customers to reuse costly SMRT cell consumables and launched a new sequencing chemistry (Sprq‑Nx) that increases output and adds...
Lila Sciences Raises $350M Series A: Nvidia Joins as investor
Flagship‑backed Lila Sciences expanded its Series A with a $115 million extension after an initial $235 million close, bringing total Series A proceeds to $350 million; the extension included...
Create Medicines Rebrands: Expands in‑vivo mRNA‑LNP immune programming
Myeloid Therapeutics announced a rebrand to Create Medicines and unveiled a strategic expansion beyond in‑vivo myeloid programming to include T‑cell and NK‑cell programming using its mRNA‑LNP...
New RC membrane outperforms columns: faster mRNA purification
Researchers at Rensselaer Polytechnic Institute reported a regenerated cellulose (RC) membrane with peptide ligands that outperformed commercial chromatography columns for purifying mRNA...
Gene therapy restores immunity in ADA‑SCID children: multicenter success
A collaborative gene‑therapy program led by UCLA, University College London and Great Ormond Street Hospital reported durable restoration of immune function in children with adenosine deaminase...
Kailera raises $600M – Prepares Zepbound‑like obesity shot for global phase 3
Kailera Therapeutics closed a $600 million Series B to fund global Phase 3 testing of KAI‑9531, a weekly injectable that targets the same receptors as Eli Lilly’s Zepbound. Bain Capital Private...
Pelage bags $120M – Topical regenerative gel moves to Phase 3
Pelage Pharmaceuticals raised $120 million in a Series B to advance its regenerative, topical gel designed to reactivate dormant hair‑follicle stem cells into Phase 3 trials next year. The round...
Tubulis raises $361M – ADC developer expands clinical footprint
Tubulis, a Munich‑based antibody‑drug conjugate (ADC) developer, closed a roughly $361 million financing to accelerate clinical testing of its lead ADCs, including TUB‑040 in ovarian and...
Novo Nordisk shells out up to $2.1B — Buys Omeros’ MASP‑3 program
Novo Nordisk agreed to acquire Omeros’ MASP‑3 inhibitor programme in a transaction worth up to $2.1 billion to advance zaltenibart, a candidate for paroxysmal nocturnal hemoglobinuria (PNH) and...
BioCryst buys Astria for ~$700M — Adds long‑acting HAE injectable
BioCryst Pharmaceuticals agreed to acquire Astria Therapeutics in a cash‑and‑stock transaction valuing Astria at about $700 million, adding navenibart — a long‑acting plasma kallikrein inhibitor...
FDA delays Denali decision — PDUFA for Hunter syndrome drug pushed three months
The FDA extended its review of Denali Therapeutics’ biologics license application for tividenofusp (tivi), an enzyme‑replacement therapy for Hunter syndrome, moving the PDUFA date by three months....
In vivo immune programming expands — Create Medicines rebrands; Liberate Bio raises seed
Create Medicines (formerly Myeloid Therapeutics) announced a strategic expansion beyond myeloid programming to include in vivo mRNA‑LNP programming of T cells and NK cells, aiming for scalable,...
AI in drug discovery accelerates — Lila adds $115M, Benchling integrates Nvidia models
Lila Sciences expanded its Series A with an additional $115 million — including investment from Nvidia’s venture arm — bringing its total haul to $350 million to fund ambitions in AI‑driven...
Sequencing price wars heat up — PacBio adds reusable consumables; Ultima pushes Solaris throughput
Pacific Biosciences unveiled a program to allow select customers to wash and reuse SMRT cell consumables and launched a new Sprq‑Nx chemistry that increases output and adds 5‑hydroxymethylcytosine...
Single‑cell scale‑up: automation meets high‑resolution multi‑omics
SPT Labtech and 10x Genomics announced a strategic partnership to automate single‑cell workflows by combining SPT’s Firefly liquid‑handling platform with 10x’s Chromium single‑cell chemistry and...
Novo Nordisk buys Omeros PNH drug: $2.1 billion deal
Novo Nordisk agreed to acquire Omeros’ stalled MASP‑3 inhibitor program, paying up to $2.1 billion to pick up the paroxysmal nocturnal hemoglobinuria (PNH) candidate and related rights. The deal...
Biocryst buys Astria – $700M pick‑up for hereditary angioedema
Biocryst Pharmaceuticals agreed to acquire Astria Therapeutics for roughly $700 million in cash and stock to add Astria’s long‑acting injectable navenibart, a plasma kallikrein inhibitor in...
Tubulis raises $361M to expand ADC program – clinical push
German antibody‑drug conjugate (ADC) developer Tubulis closed a $361 million financing to accelerate clinical development of its lead ADC, TUB‑040, and expand testing into additional tumor types...
Kailera nets $600M to carry Zepbound‑style obesity shot into Phase 3
Kailera Therapeutics secured $600 million in a Series B round led by Bain Capital Private Equity to advance KAI‑9531, a weekly injectable that targets the same receptors as established GLP‑1/GIP...
Create Medicines rebrands – in vivo mRNA CARs target T and NK cells
Create Medicines (formerly Myeloid Therapeutics) announced a rebrand and an expanded development strategy to program multiple immune cell lineages in vivo using its mRNA‑LNP platform. The company...